Capital International Ltd. CA Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY

Capital International Ltd. CA lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 78,223 shares of the biopharmaceutical company’s stock after selling 4,577 shares during the quarter. Alnylam Pharmaceuticals accounts for 1.3% of Capital International Ltd. CA’s portfolio, making the stock its 18th biggest holding. Capital International Ltd. CA owned about 0.06% of Alnylam Pharmaceuticals worth $35,670,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $662,837,000. Holocene Advisors LP purchased a new position in Alnylam Pharmaceuticals in the second quarter valued at about $194,616,000. Orbis Allan Gray Ltd raised its stake in shares of Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after acquiring an additional 486,489 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $162,577,000. Finally, Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after acquiring an additional 268,313 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Raymond James Financial reaffirmed an “outperform” rating and issued a $472.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Needham & Company LLC lowered their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Leerink Partners dropped their price target on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research note on Monday, December 15th. Finally, Barclays initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 6,799 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the sale, the chief executive officer directly owned 98,628 shares of the company’s stock, valued at approximately $32,315,464.20. This represents a 6.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $722,795.90. Following the transaction, the executive vice president owned 64,273 shares of the company’s stock, valued at approximately $21,059,048.45. The trade was a 3.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 over the last ninety days. 1.20% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Trading Up 0.9%

Shares of ALNY opened at $323.53 on Tuesday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The stock has a fifty day moving average of $350.74 and a two-hundred day moving average of $413.17. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The company has a market capitalization of $42.91 billion, a PE ratio of 189.20 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business’s revenue was up 84.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.65) EPS. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.